

Chris Reutelingsperger

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/12124404/publications.pdf>

Version: 2024-02-01

32
papers

2,381
citations

279487

23
h-index

414034

32
g-index

32
all docs

32
docs citations

32
times ranked

4023
citing authors

#	ARTICLE	IF	CITATIONS
1	Nicotine promotes vascular calcification via intracellular Ca ²⁺ -mediated, Nox5-induced oxidative stress, and extracellular vesicle release in vascular smooth muscle cells. <i>Cardiovascular Research</i> , 2022, 118, 2196-2210.	1.8	24
2	Annexin A1 treatment prevents the evolution to fibrosis of experimental nonalcoholic steatohepatitis. <i>Clinical Science</i> , 2022, 136, 643-656.	1.8	10
3	Annexin A1 attenuates cardiac diastolic dysfunction in mice with inflammatory arthritis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	14
4	Annexin A1/Formyl Peptide Receptor Pathway Controls Uterine Receptivity to the Blastocyst. <i>Cells</i> , 2020, 9, 1188.	1.8	18
5	Annexin A1 as Neuroprotective Determinant for Blood-Brain Barrier Integrity in Neonatal Hypoxic-Ischemic Encephalopathy. <i>Journal of Clinical Medicine</i> , 2019, 8, 137.	1.0	47
6	Pro-Angiogenic Macrophage Phenotype to Promote Myocardial Repair. <i>Journal of the American College of Cardiology</i> , 2019, 73, 2990-3002.	1.2	117
7	Role of Vascular Smooth Muscle Cell Phenotypic Switching and Calcification in Aortic Aneurysm Formation. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2019, 39, 1351-1368.	1.1	203
8	Identification of AnnexinA1 as an Endogenous Regulator of RhoA, and Its Role in the Pathophysiology and Experimental Therapy of Type-2 Diabetes. <i>Frontiers in Immunology</i> , 2019, 10, 571.	2.2	43
9	Targeted Imaging for Cell Death in Cardiovascular Disorders. <i>JACC: Cardiovascular Imaging</i> , 2018, 11, 476-493.	2.3	34
10	Annexin A1 attenuates microvascular complications through restoration of Akt signalling in a murine model of type 1 diabetes. <i>Diabetologia</i> , 2018, 61, 482-495.	2.9	48
11	Circulating annexin A5 levels are associated with carotid intima-media thickness but not coronary plaque composition. <i>Diabetes and Vascular Disease Research</i> , 2017, 14, 415-422.	0.9	4
12	Vascular calcification in chronic kidney disease: an update. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, 31-39.	0.4	203
13	Annexin A1-containing extracellular vesicles and polymeric nanoparticles promote epithelial wound repair. <i>Journal of Clinical Investigation</i> , 2015, 125, 1215-1227.	3.9	257
14	Endogenous annexin A1 is a novel protective determinant in nonalcoholic steatohepatitis in mice. <i>Hepatology</i> , 2014, 60, 531-544.	3.6	85
15	Noninvasive Molecular Imaging of Cell Death in Myocardial Infarction using ¹¹¹ In-GSAO. <i>Scientific Reports</i> , 2014, 4, 6826.	1.6	16
16	^{99m} Tc-HYNIC-Annexin A5 in Oncology: Evaluating Efficacy of Anti-Cancer Therapies. <i>Cancers</i> , 2013, 5, 550-568.	1.7	17
17	Annexin A1, formyl peptide receptor, and NOX1 orchestrate epithelial repair. <i>Journal of Clinical Investigation</i> , 2013, 123, 443-454.	3.9	244
18	Site-specific ⁶⁸ Ga-labeled Annexin A5 as a PET imaging agent for apoptosis. <i>Nuclear Medicine and Biology</i> , 2011, 38, 381-392.	0.3	46

#	ARTICLE	IF	CITATIONS
19	Phosphatidylserine targeting for diagnosis and treatment of human diseases. Apoptosis: an International Journal on Programmed Cell Death, 2010, 15, 1072-1082.	2.2	166
20	Fetuin-A Protects against Atherosclerotic Calcification in CKD. Journal of the American Society of Nephrology: JASN, 2009, 20, 1264-1274.	3.0	160
21	Dual molecular imaging for targeting metalloproteinase activity and apoptosis in atherosclerosis: molecular imaging facilitates understanding of pathogenesis. Journal of Nuclear Cardiology, 2009, 16, 753-762.	1.4	48
22	Molecular Imaging for Efficacy of Pharmacologic Intervention in Myocardial Remodeling. JACC: Cardiovascular Imaging, 2009, 2, 187-198.	2.3	59
23	Targeting Phosphatidylserine in Anti-Cancer Therapy. Current Pharmaceutical Design, 2009, 15, 2719-2723.	0.9	34
24	Linking Proteins with Anionic Nanoparticles via Protamine: Ultrasmall Protein-coupled Probes for Magnetic Resonance Imaging of Apoptosis. Small, 2008, 4, 225-230.	5.2	60
25	Preliminary in vivo evaluation of a novel ^{99m} Tc-labeled HYNIC-cys-annexin A5 as an apoptosis imaging agent. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 3794-3798.	1.0	38
26	Molecular Imaging of Interstitial Alterations in Remodeling Myocardium After Myocardial Infarction. Journal of the American College of Cardiology, 2008, 52, 2017-2028.	1.2	138
27	Eukaryotic expression and secretion of EGFP-labeled annexin A5. Protein Expression and Purification, 2008, 58, 325-331.	0.6	18
28	Broad and Specific Caspase Inhibitor-Induced Acute Repression of Apoptosis in Atherosclerotic Lesions Evaluated by Radiolabeled Annexin A5 Imaging. Journal of the American College of Cardiology, 2007, 50, 2305-2312.	1.2	55
29	In vitro measurement of cell death with the annexin A5 affinity assay. Nature Protocols, 2006, 1, 363-367.	5.5	81
30	Mortals turn me on. Journal of Nuclear Medicine, 2005, 46, 906-8.	2.8	3
31	Resolution of apoptosis in atherosclerotic plaque by dietary modification and statin therapy. Journal of Nuclear Medicine, 2005, 46, 2051-6.	2.8	54
32	Optimization of the preparation of ^{99m} Tc-labeled Hynic-derivatized Annexin V for human use. Nuclear Medicine and Biology, 2003, 30, 771-778.	0.3	37